OBJECT: Carbamylated erythropoietin (CEPO) is a modified erythropoietin molecule that does not affect hematocrit. In this study, the authors compared the efficacy of a single dose with a triple dose of CEPO treatment for traumatic brain injury (TBI) in rats. METHODS: Traumatic brain injury was induced by controlled cortical impact over the left parietal cortex. Carbamylated erythropoietin (50 μg/kg) was administered intraperitoneally in rats with TBI at 6 hours (CEPO × 1) or at 6, 24, and 48 hours (CEPO × 3) postinjury. Neurological function was assessed using a modified neurological severity score and foot fault and Morris water maze tests. Animals were killed 35 days after injury, and brain sections were stained for immunohistochemical analysis to assess lesion volume, cell loss, cell proliferation, angiogenesis, and neurogenesis after CEPO treatment. RESULTS: Compared with the vehicle treatment, single treatment of CEPO (6 hours) significantly reduced lesion volume and hippocampal cell loss, enhanced angiogenesis and neurogenesis in the injured cortex and hippocampus, and significantly improved sensorimotor functional recovery and spatial learning in rats after TBI. Importantly, triple dosing of CEPO (6, 24, and 48 hours) further reduced lesion volume and improved functional recovery and neurogenesis compared with the CEPO × 1 group. CONCLUSIONS: The authors' results indicate that CEPO has considerable therapeutic potential in TBI and related pathologies and furthermore that repeated dosing in the subacute phase might have important pharmacological relevance.
OBJECT: Carbamylated erythropoietin (CEPO) is a modified erythropoietin molecule that does not affect hematocrit. In this study, the authors compared the efficacy of a single dose with a triple dose of CEPO treatment for traumatic brain injury (TBI) in rats. METHODS:Traumatic brain injury was induced by controlled cortical impact over the left parietal cortex. Carbamylated erythropoietin (50 μg/kg) was administered intraperitoneally in rats with TBI at 6 hours (CEPO × 1) or at 6, 24, and 48 hours (CEPO × 3) postinjury. Neurological function was assessed using a modified neurological severity score and foot fault and Morris water maze tests. Animals were killed 35 days after injury, and brain sections were stained for immunohistochemical analysis to assess lesion volume, cell loss, cell proliferation, angiogenesis, and neurogenesis after CEPO treatment. RESULTS: Compared with the vehicle treatment, single treatment of CEPO (6 hours) significantly reduced lesion volume and hippocampal cell loss, enhanced angiogenesis and neurogenesis in the injured cortex and hippocampus, and significantly improved sensorimotor functional recovery and spatial learning in rats after TBI. Importantly, triple dosing of CEPO (6, 24, and 48 hours) further reduced lesion volume and improved functional recovery and neurogenesis compared with the CEPO × 1 group. CONCLUSIONS: The authors' results indicate that CEPO has considerable therapeutic potential in TBI and related pathologies and furthermore that repeated dosing in the subacute phase might have important pharmacological relevance.
Authors: Raj K Narayan; Mary Ellen Michel; Beth Ansell; Alex Baethmann; Anat Biegon; Michael B Bracken; M Ross Bullock; Sung C Choi; Guy L Clifton; Charles F Contant; William M Coplin; W Dalton Dietrich; Jamshid Ghajar; Sean M Grady; Robert G Grossman; Edward D Hall; William Heetderks; David A Hovda; Jack Jallo; Russell L Katz; Nachshon Knoller; Patrick M Kochanek; Andrew I Maas; Jeannine Majde; Donald W Marion; Anthony Marmarou; Lawrence F Marshall; Tracy K McIntosh; Emmy Miller; Noel Mohberg; J Paul Muizelaar; Lawrence H Pitts; Peter Quinn; Gad Riesenfeld; Claudia S Robertson; Kenneth I Strauss; Graham Teasdale; Nancy Temkin; Ronald Tuma; Charles Wade; Michael D Walker; Michael Weinrich; John Whyte; Jack Wilberger; A Byron Young; Lorraine Yurkewicz Journal: J Neurotrauma Date: 2002-05 Impact factor: 5.269
Authors: Hannelore Ehrenreich; Martin Hasselblatt; Christoph Dembowski; Lukas Cepek; Piotr Lewczuk; Michael Stiefel; Hans-Heino Rustenbeck; Norbert Breiter; Sonja Jacob; Friederike Knerlich; Matthias Bohn; Wolfgang Poser; Eckart Rüther; Michael Kochen; Olaf Gefeller; Christoph Gleiter; Thomas C Wessel; Marc De Ryck; Loretta Itri; Hilmar Prange; Anthony Cerami; Michael Brines; Anna-Leena Sirén Journal: Mol Med Date: 2002-08 Impact factor: 6.354
Authors: M L Brines; P Ghezzi; S Keenan; D Agnello; N C de Lanerolle; C Cerami; L M Itri; A Cerami Journal: Proc Natl Acad Sci U S A Date: 2000-09-12 Impact factor: 11.205
Authors: Hannelore Ehrenreich; Karin Weissenborn; Hilmar Prange; Dietmar Schneider; Christian Weimar; Katja Wartenberg; Peter D Schellinger; Matthias Bohn; Harald Becker; Martin Wegrzyn; Peter Jähnig; Manfred Herrmann; Michael Knauth; Mathias Bähr; Wolfgang Heide; Armin Wagner; Stefan Schwab; Heinz Reichmann; Günther Schwendemann; Reinhard Dengler; Andreas Kastrup; Claudia Bartels Journal: Stroke Date: 2009-10-15 Impact factor: 7.914
Authors: Ramon Diaz-Arrastia; Patrick M Kochanek; Peter Bergold; Kimbra Kenney; Christine E Marx; Col Jamie B Grimes; L T C Yince Loh; L T C Gina E Adam; Devon Oskvig; Kenneth C Curley; Wanda Salzer Journal: J Neurotrauma Date: 2014-01-15 Impact factor: 5.269